论文部分内容阅读
目的 研究干扰素α 2b(interferonα 2b ,IFNα 2b)与病毒唑 (ribavirin)联合治疗慢性丙型肝炎疗效及与IFN抗体的关系。方法 观察组 2 0例采用IFNα 2b 3MU每周 3次皮下注射 +病毒唑l0 5 0mg每天 1次口服 ,连用 2 4周 ;对照组 32例采用IFNα 2b 3MU每周 3次皮下注射 ,连用 2 4周。停药后观察 2 4周比较疗效并检测干扰素抗体。结果 观察组完全应答率为 5 0 %,明显高于对照组 18 7%;复发率为 2 5 %,低于对照组 5 6 3%。无反应率均为 2 5 %。且复发与干扰素抗体尤其是中和抗体有关。结论 干扰素与病毒唑联合治疗慢性丙型肝炎的疗效优于单独干扰素治疗组 ,复发与干扰素抗体尤其是中和抗体有关。
Objective To study the curative effect of interferon α 2b (2b) and ribavirin in the treatment of chronic hepatitis C and its relationship with IFN antibody. Methods 20 cases of observation group with IFNα 2b 3MU 3 times a week subcutaneous injection of ribavirin l050mg once daily oral administration for 24 weeks; control group of 32 patients with IFNα 2b 3MU 3 times a week subcutaneous injection, week. Observed after stopping 24 weeks to compare the efficacy and detection of interferon antibodies. Results The complete response rate of the observation group was 50%, which was significantly higher than that of the control group (18.7%). The recurrence rate was 25%, which was lower than that of the control group (56.3%). No response rate was 25%. Relapse is associated with interferon antibodies, especially neutralizing antibodies. Conclusion Interferon and ribavirin combined treatment of chronic hepatitis C is superior to interferon alone treatment group, relapse and interferon antibodies, especially neutralizing antibodies.